Recently, burosumab, a fully humanized monoclonal antibody against FGF23, was listed in the NHI drug price list in Japan for the indication of FGF23‐related hypophosphatemic rickets and osteomalacia [24, 25]. This evidence concerns the gene FGF23 and hypophosphatemic rickets.